<DOC>
	<DOCNO>NCT02490865</DOCNO>
	<brief_summary>The study aim determine effect nebulized RNS60 select biomarkers circulation .</brief_summary>
	<brief_title>Systemic Bioactivity Inhaled Nebulized RNS60</brief_title>
	<detailed_description>The study double-blind , placebo control , parallel design study . Participants randomize receive 2 daily dos either nebulised RNS60 placebo ( n=28 per group ) 22 day . On day 19 undergo exercise protocol induce muscle damage blood sample take day 19 , 20 , 21 23 determine effect CK hsCRP . ROM pain VAS assessment also complete .</detailed_description>
	<criteria>1 . The participant able read understand Informed Consent Form ( ICF ) , understand study procedure . 2 . The participant sign ICF . 3 . Healthy male female participant age 1845 year inclusive . Attempts make achieve equal gender ratio appropriate screening procedure , failure preclude analysis final data set . 4 . BMI 19 27 kg/m2 . 5 . The participant , opinion investigator , healthy basis medical history vital sign . 6 . Available followup duration study . 7 . Nonsmokers ( smoke use nicotine replacement ( include ecigarettes ) previous month screen study ) 8 . Agree abstain donate blood study . 9 . Men woman reproductive potential document use adequate contraception study 1 month follow last day treatment ( Day 23 ) 10 . Willing refrain take antiinflammatory medication study ( particularly ibuprofen ) . 1 . Clinically significant psychiatric , cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurological ( particularly myasthenia gravis ) , immunological , haematological disease abnormality , determine study physician . 2 . History alcohol , narcotic , benzodiazepine , substance abuse dependence within 12 month precede Visit 1 . 3 . History significant musculoskeletal upper limb injury . 4 . Participating regular ( â‰¥ 2 time per week ) upper body resistance exercise training within 6 week Visit 1 . 5 . FEV1 &lt; 80 % FEV1/FEC &lt; 75 % 6 . Use steroid immunosuppressive/immunomodulating drug either orally parenterally within 3 month Visit 1 . 7 . Use NSAIDs OTC medication within 2 week Visit 1 . 8 . Use dietary/nutritional supplement , include vitamin mineral , 2 week Visit 1 . 9 . Positive urinary pregnancy test . 10 . Pregnant lactate point study screen final visit . 11 . Following weight reduce diet . 12 . Currently participate another clinical trial investigational noninvestigational drug device , participate another clinical trial within 3 month precede Visit 1 . 13 . Any condition , investigator 's opinion , compromise participant 's ability meet protocol requirement complete study . 14 . Receipt blood product immunoglobin , within 3 month visit 1 . 15 . Unable read speak English fluency level adequate full comprehension procedure require participation consent . No waiver Protocol allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>